Location Directory

Clinical trials in Jacksonville, Florida

This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7646

Shown on this page

Current sort

Institutions in Jacksonville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Mayo Clinic

Live official records

Open in full search

Conditions: Major Depressive Disorder
Interventions: BHV-7000; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 66
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm, Brain Aneurysm
Interventions: Flow diversion; Device
Lead sponsor: phenox Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 21 more

Conditions: Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions: Solriamfetol 150 MG, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 40
States / cities: Tucson, Arizona • Bellflower, California • Chino, California + 33 more

Conditions: Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis
Interventions: Not listed
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2033
U.S. locations: 13
States / cities: La Jolla, California • Los Angeles, California • Jacksonville, Florida + 10 more

Conditions: Autosomal Dominant Polycystic Kidney Disease
Interventions: AZD1613 - Part A, Placebo - Part A, AZD1613 - Part B, Placebo - Part B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Loma Linda, California • Jacksonville, Florida + 5 more

Conditions: Prostate Cancer
Interventions: iRAI; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Major Depressive Disorder
Interventions: Azetukalner, Placebo; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 45
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 38 more

Conditions: Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neuroblastoma
Interventions: Biopsy Procedure, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Clinical Observation, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Magnetic Resonance Imaging, Ultrasound; Procedure · Drug · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 18 Months
Enrollment: 391 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 193
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more

Conditions: Higher-risk Myelodysplastic Syndrome
Interventions: Lisaftoclax (APG-2575), Azacitidine Injection, Placebo; Drug · Other
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 36 more

Conditions: Bipolar Disorder, Bipolar Depression, Bipolar I Disorder, Bipolar II Disorder
Interventions: Azetukalner, Placebo; Drug
Lead sponsor: Xenon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 34
States / cities: Tucson, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 29 more

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Topical corticosteroids, Topical tacrolimus or pimecrolimus; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Scottsdale, Arizona • North Little Rock, Arkansas + 36 more

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitors, Oral corticosteroids; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1,856 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 101
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 77 more

Clinical trials in Jacksonville, Florida

Filter and sort this location

Institutions in Jacksonville

Live official records

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning

A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).

A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials